DENVER, Dec. 3 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disease, today announced that Joseph L. Turner, Chief Financial
Officer and Senior Vice President Finance and Administration, will present a
corporate overview at the First Albany Capital Annual Growth Conference.
The presentation will take place at 9:20 a.m. (Eastern) on Wednesday,
December 8, 2004. There will be a live webcast of the presentation, which
will be accessible through a link posted on the investor relations section of
the Myogen website at http://investor.myogen.com/. The webcast will be
available for replay on Myogen's website through December 24, 2004.
Myogen currently markets one product (Perfan(R) I.V.) in Europe for the
treatment of acute decompensated heart failure and has three product
candidates in late-stage clinical development: enoximone capsules for the
treatment of chronic heart failure, ambrisentan for the treatment of pulmonary
arterial hypertension and darusentan for the treatment of resistant
hypertension. The Company, in collaboration with Novartis, also conducts a
target and drug discovery research program focused on the development of
disease-modifying drugs for the treatment of chronic heart failure and related
cardiovascular disorders. Please visit our website at http://www.myogen.com.
Safe Harbor Statement
This press release and the anticipated presentation contain forward-
looking statements that involve significant risks and uncertainties, including
those discussed in this release, those to be discussed in the presentation and
others that can be found in the "Risk Factors" section of Myogen's Form 10-K
for the year ended December 31, 2003 and in Myogen's periodic reports on
Form 10-Q and Form 8-K. Myogen does not undertake any obligation to update
any forward-looking statements contained in this document or the anticipated
presentation as a result of new information, future events or otherwise. The
Company cautions investors not to place undue reliance on the forward-looking
statements contained in this press release or the presentation. No forward-
looking statement can be guaranteed and actual events and results may differ
materially from those projected.
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations,
Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
